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Abstract 
This review analyses current data concerning co-infection 
with hepatitis C virus (HCV) and human T lymphotropic 
virus (HTLV)-1/2 in people who inject drugs (PWID), 
with a particular focus on disease burden and global 
implications for virological outcome. In addition, the 
available treatment options for HTLV-1/2 are summarized 
and the ongoing and likely future research challenges are 
discussed. The data in this review was obtained from 34 
articles on HCV/HTLV-1/2 co-infection in PWID retrieved 
from the PubMed literature database and published 
between 1997 and 2015. Despite unavailable estimates 
of the burden of HCV/HTLV-1/2 co-infection in general, 
the epidemiologic constellation of HTLV-1/2 shows high 
incidence in PWID with history of migration, incarceration, 
and other blood-borne infectious diseases such as HCV 
or human immunodeficiency virus. The most recent 
research data strongly suggest that HTLV-1 co-infection 
can influence HCV viral load, HCV sustained virological 
response to α-interferon treatment, and HCV-related liver 
disease progression. In short, outcome of HCV infection 
is worse in the context of HTLV-1 co-infection, yet more 
studies are needed to gain accurate estimations of the 
burden of HCV/HTLV-1/2 co-infections. Moreover, in the 
current era of new direct-acting antiviral treatments for 
HCV and proven HTLV-1/2 treatment options, prospective 
clinical and treatment studies should be carried out, with 
particular focus on the PWID patient population, with the 
aim of improving virological outcomes.
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infections. Co-infections with human immunodeficiency 
virus and human T lymphotropic virus (HTLV)-1/2 are 
common, and well-studied, among PWID; however, the 
rise of HTLV-1/2 co-infections with hepatitis C virus (HCV) 
has gained much research attention and studies have 
shown that the former influences the chronic disease 
course of the latter. This review summarizes the data from 
34 articles on HCV/HTLV-1/2 co-infection in the PWID 
patient population, including current treatment options 
and impact on virological outcome.
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HEPATITIS C VIRUS AND HUMAN T 
LYMPHOTROPIC VIRUS-TYPES 1/2 CO-
INFECTION BURDEN 
The rate of hepatitis C virus (HCV) infection has reached 
the level of a global epidemic, with an estimated burden 
of 2.8% seroprevalence (anti-HCV antibody) in over 185 
million individuals from both developed and developing 
nations[1]. In Europe and the United States, however, HCV 
transmission occurs mainly through intravenous drug 
use[2,3]. While this practice facilitates spread of blood-borne 
viruses, including the human immunodeficiency virus (HIV) 
as well as the hepatitis B virus, it allows transmission of 
HCV much more efficiently, as evidenced by the higher 
incidence rates of HCV in people who inject drugs (PWID) 
vs those with HIV[3]. Specifically, the 2011 estimate of 
global PWID seroprevalence for HCV was 67.0%[4]. PWID 
are a select population subgroup with extremely high 
seroprevalences of HCV; as such, they represent a primary 
driving force of the current HCV epidemic in high-resource 
settings, accounting for the majority of new (80%) and 
existing (60%) cases reportedly[5]. Yet, the high proportion 
of undiagnosed asymptomatic HCV carriers has precluded 
obtainment of an accurate estimate of chronic hepatitis C 
burden.  
Human T lymphotropic virus (HTLV)-1 is an oncogenic 
retrovirus with a similar worldwide incidence. Although its 
founder effect remains unresolved, HTLV-1 shows high 
endemicity in Southwestern Japan, sub-Saharan Africa, 
South America, the Caribbean basin, the Middle East, and 
Australo-Melanesia[6]. The worldwide prevalence estimate 
of 20 million infected people is based on a serological 
screening from nearly 30 years ago, and an accurate 
estimate of the current global burden is unavailable[7]. 
The main transmission routes are contaminated blood 
products, sexual intercourse, and vertical transmission. 
In Europe, most HTLV-1 carriers are descendants of 
immigrants originally from regions with high endemicity 
and often with an HIV co-infection[6,7]. However, as 
reported for Spain, Italy and Ireland, PWID represent an 
especially affected population for HTLV-1 infection, even 
though HTLV-2 is much more prevalent[6].  In contrast, 
clinical onset of associated chronic illnesses, such as 
cancer [adult T-cell leukaemia/lymphoma (ATLL)] and 
neurological disorders [myelopathy and tropical spastic 
paraparesis (HAM/TSP)], has been reported in only 
5%-10% of HTLV-1 carriers[8-10]. 
Similar to HTLV-1, HTLV-2 can be transmitted intra-
venously, sexually, or vertically. In the United States 
and Europe, needle sharing is a major route of HTLV-2 
transmission among the PWID population[11-13]. Moreover, 
study of a cohort of PWID in the United States revealed 
significant associations between HTLV-2 infection and 
increased rates of pneumonia, acute bronchitis, urinary 
tract infection, and myelopathy[14], and the authors noted 
that the observed high correlation of HTLV-2 infection with 
HCV infection was suggestive of injection practices as a 
major route of transmission.  
Studies of retroviral transmission carried out in various 
developing countries have identified incarceration as a risk 
factor, especially for HCV, suggesting that incarceration 
may be a surrogate marker for risky behaviour in 
general, such as needle sharing and unprotected sex[14]. 
In addition, our previous case report of HTLV in Eastern 
European countries indicated that the criminalization of 
drug use and lack of harm reduction strategies in prisons 
may also serve to increase risk for sexual and parental 
transmission[15].  
Finally, the contribution of health care-associated 
infection (or “nosocomial”) as a source of HCV and retro-
virus transmission among migrant population originally 
coming from limited resources settings has been largely 
undervalued to date, with little research available[16]. The 
limited data reported has shown nosocomial rates ranging 
from as low as 5% and all the way up to 19%[16].
In conclusion, the epidemiological constellation of 
HCV/HTLV-1/2 co-infection is found within regions with 
high rates of PWID and history of other risk factors 
(Figure 1). 
CLINICAL AND THERAPEUTIC 
IMPLICATIONS OF HCV/HTLV-1/2 CO-
INFECTION
In order to gain a comprehensive overview of the current 
available knowledge on the clinical and therapeutic 
implications of HCV/HTLV-1/2 co-infection, we searched 
the PubMed (www.pubmed.gov) literature database for 
all articles affiliated with the terms “HTLV HCV”, “HCV and 
HTLV coinfection”, “HTLV burden”, “HTLV treatment”, and 
“HTLV migrants”. Exclusion of articles published before 
January 1, 1990 left a total of 34 studies for review. 
Clinical implications of HCV/HTLV-1/2 co-infection 
A large-scale survey of residents of Iki Island in Japan, 
an endemic region for HTLV-1 infection, conducted by 
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Kishihara et al[17] showed that individuals with HCV/
HTLV-1 co-infection had a lower rate of natural clearance 
of HCV RNA and of sustained virological response to 
interferon (IFN) treatment than their counterparts with 
HCV infection alone; moreover, the co-infected population 
showed significantly higher HCV viremia (P < 0.05). 
Other Japanese studies of HCV/HTLV-1 co-infection in 
PWID showed associations with liver disease (6-fold 
increased risk)[18] and liver cancer mortality (2.6-fold 
increased risk)[19], leading to the hypothesis of an 
HTLV-1–induced immune modulation and inflammatory 
cytokine dysregulation that could affect HCV persistence 
and progression to liver disease[20,21]. In contrast to the 
Japanese findings, however, two Brazilian studies[22,23] 
of HCV/HTLV-1 co-infection provide epidemiological and 
immunological evidence of a higher rate of spontaneous 
clearance of HCV in patients with HIV/HTLV-1 co-infection 
as compared to patients harbouring only an HIV/HCV 
co-infection or an HCV mono-infection. The differences 
between HCV and HTLV-1 interaction outcomes in these 
two settings may be due to host genetic factors (e.g., 
HLA genotypes), study design, or other unmeasured 
parameters of the study populations. Studies of the 
molecular underpinnings of the HCV and HTLV-1 
interaction outcomes have shown that HTLV-1-infected 
T cells, together with viral gene expression and cellular 
signalling mechanisms, can trigger a strong virus-specific 
immune response and increased proinflammatory 
cytokine production[24,25]. Moreover, the cellular immune 
response has been implicated in the control of HTLV-1 
infection as well as in the development of related 
inflammatory alterations in patients[26]. The cellular 
immune response involves CD4+ T cells differentiating 
towards the Th1, Th2 and Th17 lineages, producing 
a variety of proinflammatory cytokines, chemokines, 
adhesion molecules and proinflammatory enzymes, 
which contribute to chronic inflammatory conditions 
and include reactive oxygen species (ROS), tumour 
necrosis factor alpha (TNFα), interleukins (IL1, 6, 8 and 
18), nuclear factor-kappa B (NF-κB), hypoxia-inducible 
factor (HIF), IFNγ, and cyclooxygenase (COX)[27,28]. 
Moreover, contributions of different HTLV-1 oncogenic 
pathways related to viral proteins have been recently 
described recently[29]. Additionally, a study of 199 HTLV-1 
infected subjects by Treviño et al[30] showed that the risk 
of developing TSP was 10-times higher among HTLV-1 
carriers who harboured the IL B-28 CT and TT alleles 
than their counterparts who harboured the CC allele. 
The same study also showed an association between 
the CT polymorphism and increased HTLV-1 viral loads, 
and that the CC allele is found more frequently among 
asymptomatic carriers of HTLV-1 (62%). Collectively, 
these data strongly suggest that HTLV-1 co-infection 
plays a role in HCV viremia and evolution, attainment 
of HCV sustained virological response to α-interferon 
treatment, and HCV-related liver disease progression. 
Briefly, the current evidence supports postulation of 
worsening of HCV infection in the context of HTLV-1 co-
infection.
Treatment implications of HCV/HTLV-1/2 co-infection
HTLV-1/2 asymptomatic carriers do not require treatment. 
However, for HTLV-1/2 carriers who experience clinical 
onset of ATLL or HAM/TSP the current treatment options 
are limited and those available have a suboptimal range 
of efficacy. A meta-analysis of ATLL antiviral therapies 
showed that α-IFN and zidovudine (AZT) combination 
can induce complete remission and produce a high 
(82%) 5-year survival rate in ATLL patients[31]. Another 
ATLL therapeutic approach, specifically the α-interferon, 
arsenic and AZT combination, was evaluated in a later 
study of 16 patients and showed induction of a beneficial 
cytokine modulation response with a shift from the pre-
treatment Treg/Th2 phenotype to the Th1 phenotype 
post-treatment[32]. Thus, this triple drug combination 
may be a useful treatment approach to restore an 
immuno-competent microenvironment, which will 
enhance the eradication of ATL cells and the prevention 
of opportunistic infections. Yet another study evaluated 
the combination of valproate (VPA) and AZT in patients 
with advanced HAM/TSP and found that the treatment 
may control viral replication through inhibition of the virus 
reverse-transcriptase and/or its associated molecular 
machinery[33]. The same strategy has been evaluated 
in non-human primates (Papio papio) naturally infected 
with the simian T cell lymphotropic virus type 1 (STLV-1; 
the equivalent of HTLV-1 which also causes simian ATLL). 
The animals were asymptomatic carriers and treatment 
with AZT/VPA induced a reduction of viral load which 
relapsed after treatment interruption[34]. A study of the 
HIV integrase inhibitor drug, raltegravir, as treatment for 
HTLV-1 (evaluating 5 carriers, including 2 with HAM and 3 
asymptomatic) showed achievement of a transitory viral 
load reduction during the 24 wk of treatment but with no 





Figure 1  Global risk factors for co-infection with hepatitis C virus and 
human T lymphotropic virus-1/2 in people who inject drugs. Adapted from 
Roger and Castro, 2014[15]. In this model, each circle represents a risk factor of 
hepatitis C virus (HCV)/human T lymphotropic virus-1/2 co-infection in people 
who inject drugs in the context of global migration patterns and increased health 
care-associated infections (HCAI; also known as “nosocomial” or “hospital-
based” infections) in settings with limited resources, incarceration (particularly in 
countries that lack harm-reduction programs for incarcerated populations), and 
in the background of human immunodeficiency virus (HIV) or HCV infection.
Castro E et al . HCV/HTLV-1/2 co-infection in intravenous drug users
71 May 12, 2016|Volume 5|Issue 2|WJV|www.wjgnet.com
et al[36] reported the only study to date in our collected 
articles from the PubMed literature to assess the evolution 
of HTLV co-infection (including with HIV, HTLV-2 and HCV) 
among patients who received treatment for HCV and 
showed reduction of HTLV-2 viral load in response to the 
α-IFN and ribavirin combination treatment.
DISCUSSION AND FUTURE PROSPECTS 
The main features of HCV/HTLV-1/2 co-infection, based 
on evidence reported in the current literature, are 
summarized in Table 1. Briefly, they highlight the role 
of PWID as a core affected population and the negative 
immune modulation effect of HTLV-1 co-infection in 
patients with chronic hepatitis C. At the same time, HCV/
HTLV-1/2 co-infection remains an unresolved clinical 
challenge; prospective studies looking at the HTLV-1/2 
infection outcome in subjects receiving new direct-acting 
antiviral treatments targeting the HCV infection will likely 
provide further insights towards improvement.
The features listed in Table 1 are a source of new 
research questions to be addressed. In addition, they 
should challenge the clinical field to reflect on the pertinence 
of adding HTLV-1/2 screening for PWID patients and 
particularly in relation to caring for migrant populations from 
high endemic areas in different worldwide settings.
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